AEGiS-PRn: New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline PRNewswireImportant note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Click here to return to PRNewswire main menu
DonateNow


New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline

PRNewswire - December 10, 2007


JACKSON, Miss., Dec. 10 /PRNewswire-USNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) delivered a new report on medicines in the research pipeline for major diseases affecting African Americans to Mississippi Governor Haley Barbour today. The report found that America's pharmaceutical research companies are now testing 691 new medicines to help treat diseases that disproportionately affect African Americans or diseases that are among the top 10 causes of death among African Americans. According to the U.S. Census Bureau, Mississippi has the largest (37 percent) African American population in the United States.

"We delivered this report to Governor Barbour because of it's relevance to the health of Mississippi's African American population," said Ken Johnson, PhRMA Senior Vice President. "The diseases highlighted in the report, including cancer, diabetes, heart disease and stroke, are among the diseases that disproportionately affect African Americans in Mississippi."

For example, according to state statistics, African Americans in Mississippi have a mortality rate from cardiovascular disease that is 25 percent higher than whites, stroke is 66 percent higher than whites, and African Americans in Mississippi are almost twice as likely as whites to have diabetes.

"There are complex reasons for the health disparity between African Americans and other Americans that are not fully understood," said PhRMA President and CEO Billy Tauzin. "These 691 medicines in development offer hope for closing the troubling health gap and increase the likelihood that every American can share in the benefits of medical progress."

The medicines in development include:

-- 229 medicines for cancers that disproportionately affect African Americans. According to the American Cancer Society, African Americans have the highest mortality rate of any racial and ethnic group for all cancers combined.

-- 114 medicines designed to treat cardiovascular disease. According to the American Heart Association, African Americans have the highest prevalence rate of high blood pressure in the world.

-- 95 medicines in development for diabetes. According to the American Diabetes Association, African Americans are nearly two times more likely to have diabetes compared with whites.

-- 77 medicines for respiratory disorders, including asthma. According to the American Lung Association, African Americans have the highest asthma rate of any other racial and ethnic group. They are also three times more likely to die from asthma than whites.

-- 67 medicines that target HIV infection. Although the overall estimated numbers of new HIV infections have been decreasing, African Americans accounted for 49 percent of cases of HIV infection diagnosed in 2005, according to the U.S. Centers for Disease Control and Prevention.

Other medicines in development tackle kidney disease, glaucoma, obesity, and sickle cell disease.

To read the report on the PhRMA Web site, click on the following link: http://www.phrma.org/

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $43 billion in 2006 in discovering and developing new medicines. Industry wide research and investment reached a record $55.2 billion in 2006.

PhRMA Internet Address: http://phrma.org/

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://innovation.org/

For information on the Partnership for Prescription Assistance, visit: http://pparx.org/

For information on the danger of imported drugs, visit: http://buysafedrugs.info/

Source: Pharmaceutical Research and Manufacturers of America

CONTACT: Telly Lovelace of the Pharmaceutical Research and Manufacturers of America, +1-202-835-3460

Web Site: http://buysafedrugs.info/

http://innovation.org/

http://pparx.org/

http://sharingmiracles.com/

http://www.phrma.org/


071210
PR071221


Copyright © 2007 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019  http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .